Lacosamid Hikma (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and reducing repetitive neuronal firing. This mechanism diminishes hyperexcitability in the brain, which is a key factor in seizure generation.

The specific dose of Lacosamid Hikma is determined by the prescribing clinician based on the patient’s clinical condition, age, renal function, and concomitant therapies. Dosage adjustments are made to achieve optimal seizure control while minimizing side effects.

Safety data in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lacosamide differs from many traditional antiepileptics by selectively enhancing slow sodium‑channel inactivation, which may result in fewer cognitive side effects compared with drugs like carbamazepine or phenytoin. Its intravenous formulation also offers rapid onset for acute seizure management.

Lacosamid Hikma should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, inspect the solution for particulate matter and ensure the vial is within its expiry date.

The product is supplied as an intravenous solution and is administered by slow infusion under the supervision of a qualified healthcare professional. The infusion rate and total daily dose are individualized by the prescriber based on therapeutic response.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, atrial fibrillation, severe skin reactions (e.g., Stevens‑Johnson syndrome), and emergence of suicidal thoughts or behaviors. Prompt medical evaluation is required if any of these events occur.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid use. Caution is also advised for individuals with significant cardiac disease, severe renal impairment, or those taking interacting medications that may increase cardiac risk.